Upon
successfully trying a promising Ebola vaccine on monkeys, the United States has
started tracking Ebola vaccine on human beings.
The
human trial of the vaccine is expected to be extended to Africa, where the
virus disease has killed thousands, and the UK.
Experiments
conducted by the US National Institutes of Health revealed that Monkeys
developed long-term immunity to the virus ─ for as long as 10 months ─ after
being exposed to the trial drug. Continue
Animal
research which informed the decision to begin human trials has now been
published in the journal, Nature Medicine.
The
Director of the US National Institute of Allergy and Infectious Diseases, Dr
Anthony Fauci, told the BBC that: “The good part of this vaccine is that at
five weeks or earlier, you get full protection. “The sobering news is the
durability isn’t great, but if you give a boost, a second shot, you make it
really durable.”
Emphasizing
that healthcare providers and other frontline staff would be prioritized for
vaccination, Dr Fauci said: “We knew this worked in the monkey months ago and
based on this paper, we started human trials.”
Going
by reports, several experimental treatments are currently being considered to
help contain the spread of Ebola, including a vaccine being developed by the US
National Institute of Allergy and Infectious Diseases, and the pharmaceutical
company GlaxoSmithKline.
A
BBC report informs that this treatment uses a genetically modified chimp virus
containing components of two species of Ebola – Zaire, which is currently
circulating in West Africa, and the common Sudan species. Since the viral
vaccine does not replicate inside the body, it is hoped that the immune system
gets to react to the Ebola component of the vaccine and develop anti-body.
More
than 2,000 people have died in the outbreak of the deadly disease in West Africa,
with Nigeria accounting for eight deaths, Liberia-1,089, Guinea -517 and Sierra
Leone-491.
The
disease was brought to Nigeria by a Liberian-American, Patrick Sawyer, who died
in Lagos.
No comments:
Post a Comment